Pharmaceutical Industry Payments to Diagnostic Radiologists

Area of Science:

• Medical Economics
• Radiology
• Healthcare Policy

Background:

• The Physician Payments Sunshine Act (PPSA) of 2010 promotes transparency in industry-physician financial relationships.
• Understanding these financial ties is crucial for assessing potential influences on medical practice and patient care.
• Diagnostic radiology (DR) relationships with industry require specific examination, especially when compared to fields like oncology.

Purpose of the Study:

• To analyze industry payment data for diagnostic radiologists (DR) from 2012 to 2020.
• To compare the financial relationships of DR with those of oncologists.
• To identify trends and key industry contributors in payments to DR.

Main Methods:

• Data on industry payments to physicians was extracted from the Open Payments database.
• Payments to diagnostic radiologists and oncologists were collected and analyzed.
• Statistical analysis was performed using IBM SPSS, with significance set at P < 0.05.

Main Results:

• From 2012-2020, DR received 178,957 industry payments totaling over $275 million, with average cash and in-kind payments of $1529 and $223, respectively.
• Pharmaceutical companies, including Merck Sharp and Dohme, Hologic, and Pfizer, were top payers to DR.
• While oncology received more total payments until 2019, DR physicians began receiving higher total payment values thereafter and obtained payments with 10x greater average value per transaction.

Conclusions:

• Diagnostic radiologists receive significant financial value from industry, particularly pharmaceutical companies.
• There is a notable shift, with DR physicians experiencing a steep uptrend in payment value from 2019-2021, contrasting with a downtrend for oncologists.
• Increased transparency into these evolving industry-radiology relationships is vital for understanding their impact on patient care.